Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease

Neuroscience

Volumn 163, Issue 1, 2009, Pages 456-465

  Dowie, M J ^a   Bradshaw, H B ^b   Howard, M L ^c   Nicholson, L F B ^a   Faull, R L M ^a   Hannan, A J ^c   Glass, M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CB1; dopamine; endocannabinoid; GABA; neurodegeneration; R6 1 mice

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID A RECEPTOR; ANANDAMIDE; CANNABINOID 1 RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ENDOCANNABINOID; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; FEMALE; GENE EXPRESSION; GLOBUS PALLIDUS; HIPPOCAMPUS; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; ARACHIDONIC ACIDS; BINDING, COMPETITIVE; BRAIN; CANNABINOIDS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DYSKINESIAS; ENDOCANNABINOIDS; GLYCERIDES; HIPPOCAMPUS; HUNTINGTON DISEASE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE; RNA, MESSENGER; SUBSTANTIA NIGRA;

EID: 68349152770     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.06.014     Document Type: Article

References (48)

1. Battista N., Bari M., Tarditi A., Mariotti C., Bachoud-Levi A.C., Zuccato C., Finazzi-Agro A., Genitrini S., Peschanski M., Di Donato S., Cattaneo E., and Maccarrone M. Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol Dis 27 (2007) 108-116
2. Bisogno T., Martire A., Petrosino S., Popoli P., and Di Marzo V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem Int 52 (2008) 307-313
3. Bradshaw H.B., Rimmerman N., Krey J.F., and Walker J.M. Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am J Physiol Regul Integr Comp Physiol 291 (2006) R349-R358
4. Centonze D., Rossi S., Prosperetti C., Tscherter A., Bernardi G., Maccarrone M., and Calabresi P. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol Psychiatry 57 (2005) 1583-1589
5. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., and Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23 (2003) 961-969
6. Cepeda C., Starling A.J., Wu N., Nguyen O.K., Uzgil B., Soda T., Andre V.M., Ariano M.A., and Levine M.S. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res 78 (2004) 855-867
7. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney Jr. J.B., Davies S.W., Bates G.P., and Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci 354 (1999) 981-989
8. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., and Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci U S A 95 (1998) 6480-6485
9. Denovan-Wright E.M., and Robertson H.A. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98 (2000) 705-713
10. Egertova M., Cravatt B.F., and Elphick M.R. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119 (2003) 481-496
11. Faull R.L., Waldvogel H.J., Nicholson L.F., and Synek B.J. The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat. Prog Brain Res 99 (1993) 105-123
12. Glass M. The role of cannabinoids in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 25 (2001) 743-765
13. Glass M., Dragunow M., and Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 (2000) 505-519
14. Glass M., Faull R.L., and Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56 (1993) 523-527
15. Glass M., van Dellen A., Blakemore C., Hannan A.J., and Faull R.L. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123 (2004) 207-212
16. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87 (1990) 1932-1936
17. Hickey M.A., Reynolds G.P., and Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J Neurochem 81 (2002) 46-59
18. Ho L.W., Carmichael J., Swartz J., Wyttenbach A., Rankin J., and Rubinsztein D.C. The molecular biology of Huntington's disease. Psychol Med 31 (2001) 3-14
19. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., and Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 51 (2002) 235-242
20. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
21. Kofalvi A., Rodrigues R.J., Ledent C., Mackie K., Vizi E.S., Cunha R.A., and Sperlagh B. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 25 (2005) 2874-2884
22. Lastres-Becker I., Berrendero F., Lucas J.J., Martin-Aparicio E., Yamamoto A., Ramos J.A., and Fernandez-Ruiz J.J. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res 929 (2002) 236-242
23. Lastres-Becker I., Fezza F., Cebeira M., Bisogno T., Ramos J.A., Milone A., Fernandez-Ruiz J., and Di Marzo V. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport 12 (2001) 2125-2129
24. Laviolette S.R., and Grace A.A. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 63 (2006) 1597-1613
25. Lopez-Moreno J.A., Gonzalez-Cuevas G., Moreno G., and Navarro M. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict Biol 13 (2008) 160-187
26. Maccarrone M., Battista N., and Centonze D. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog Neurobiol 81 (2007) 349-379
27. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
28. Matsuda L.A., Bonner T.I., and Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327 (1993) 535-550
29. Mazarakis N.K., Cybulska-Klosowicz A., Grote H., Pang T., Van Dellen A., Kossut M., Blakemore C., and Hannan A.J. Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice. J Neurosci 25 (2005) 3059-3066
30. McCaw E.A., Hu H., Gomez G.T., Hebb A.L., Kelly M.E., and Denovan-Wright E.M. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 271 (2004) 4909-4920
31. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20 (2000) 5115-5123
32. Naver B., Stub C., Moller M., Fenger K., Hansen A.K., Hasholt L., and Sorensen S.A. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 122 (2003) 1049-1057
33. Nicholson L.F.B. Processing human brain tissue for in situ hybridization with radiolabelled oligonucleotides. In: Wisden W., and Morris B. (Eds). In situ hybridization protocols for the brain, Vol. 47 (2002), Academic Press, London 105-116
34. A receptor subunit subtypes in the human putamen and globus pallidus in Huntington's disease-an in situ hybridisation study. In: Ohye C., et al. (Ed). The basal ganglia V (1996), Plenum Press, New York 433-440
35. A receptor subunit mRNA's in the human thalamus. In: Abstract P10c Australian Neuroscience Society, 19th annual meeting.
36. Nicniocaill B., Haraldsson B., Hansson O., O'Connor W.T., and Brundin P. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur J Neurosci 13 (2001) 206-210
37. Nithianantharajah J., Barkus C., Murphy M., and Hannan A.J. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol Dis 29 (2008) 490-504
38. Page K.J., Besret L., Jain M., Monaghan E.M., Dunnett S.B., and Everitt B.J. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia. Exp Brain Res 130 (2000) 142-150
39. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grubler Y., Stalla J., Arzberger T., Milone A., Losa M., Di Marzo V., Lutz B., and Stalla G.K. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 86 (2001) 2687-2696
40. Pang T.Y., Stam N.C., Nithianantharajah J., Howard M.L., and Hannan A.J. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. Neuroscience 141 (2006) 569-584
41. Richfield E.K., and Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36 (1994) 577-584
42. Spires T.L., Grote H.E., Varshney N.K., Cordery P.M., van Dellen A., Blakemore C., and Hannan A.J. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 24 (2004) 2270-2276
43. Starowicz K., Nigam S., and Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114 (2007) 13-33
44. Toth A., Boczan J., Kedei N., Lizanecz E., Bagi Z., Papp Z., Edes I., Csiba L., and Blumberg P.M. Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 135 (2005) 162-168
45. Trottier Y., Biancalana V., and Mandel J.L. Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J Med Genet 31 (1994) 377-382
46. van Dellen A., Blakemore C., Deacon R., York D., and Hannan A.J. Delaying the onset of Huntington's in mice. Nature 404 (2000) 721-722
47. Wilson R.I., and Nicoll R.A. Neuroscience-endocannabinoid signaling in the brain. Science 296 (2002) 678-682
48. Wisden W., and Morris B. In situ hybridization protocols for the brain (2002), Academic Press, London